Panav Bio-Tech Witnesses Increased Demand for Canglob P Hyperimmune Immunoglobulins After Parvovirus Outbreak in West Bengal

February 26, 2021 03:32 AM IST | By NewsVoir
 Panav Bio-Tech Witnesses Increased Demand for Canglob P Hyperimmune Immunoglobulins After Parvovirus Outbreak in West Bengal
Image source: NewsVoir

As a huge number of street dogs died due to the canine Parvovirus in West Bengal, the New Delhi-based Company Panav Bio-Tech which is the importer and marketer of 'Canglob P', hyperimmune immunoglobulins for Parvovirus, said there is a sudden increase in the demand of the hyperimmune immunoglobulin for dogs.

Canglob P, Hyperimmune Immunoglobulin against Parvovirus

The company has witnessed an increase in demand for Canglob P after the outbreak of the Parvovirus.

Parvovirus is a highly contagious and deadly viral disease that affects dogs, especially puppies. The mortality rate for this virus is high.

Canine Distemper is highly contagious and potentially fatal. It causes severe illness in the dog by attacking multiple body systems, resulting in widespread infection.

As far as treatment goes, Panav Bio-Tech provides Canglob hyperimmune immunoglobulins that can help in treating dogs who have contracted Parvovirus or Distemper Virus. Both the Canine Parvovirus and Canine Distemper Virus are deadly for dogs. These hyperimmune immunoglobulins are used to provide passive immunity in animals.

Canglob P and Canglob D forte have readymade antibodies for Pre and Post Exposure of Parvovirus and Distemper. It is a definite help to your vet. The earlier the puppies are diagnosed, the faster they receive treatment, the better their chance of recovery.

Sharing the information, Director Import/Marketing of Panav Bio-Tech, Mr. Puneet Chopra said, "We have endeavoured to provide effective vaccination and Canglob hyperimmune immunoglobulins against fatal diseases. Parvovirus is highly contagious and fatal so we request the pet owners to take extra care of their pets. Parvovirus spreads directly through contact with infected dogs and indirectly through infected faeces or vomiting. Since dogs are well-known lickers, they can lick contaminated paws or another infected dog and can cause the disease."

About Panav Bio-Tech

Panav Bio-Tech was established in 2005 with the objective of animal health care and today it is one of the dominant companies of healthcare products in India.

The company is headquartered in New Delhi, it is a registered company with the Government of India for the import of veterinary biologicals, therapeutic solutions and innovative nutraceuticals.

With a portfolio of bio preparations especially vaccines against the menacing diseases, curative solutions to specific pathologies and pioneering nutraceuticals products for the robustness and well-being of animals.

The corporate ideology to construct consciousness regarding the relevance of vaccines in animals life and serve the animal race with quality vaccines at economical prices to enhance their quality of life. The ethics and beliefs such as virtuosity, eminence, fidelity, faith and gratitude make Panav Bio-Tech a company that stands out in the veterinary world. The innovations, service orientation, drive towards achieving success and an attitude of being triumphant against all the odds by leaving no stones unturned are the qualities that are at the heart of Panav Bio-Tech.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.